Cyteir Therapeutics, Inc. (CYT): Price and Financial Metrics
GET POWR RATINGS... FREE!
CYT Stock Price Chart Interactive Chart >
CYT Price/Volume Stats
| Current price | $2.04 | 52-week high | $23.10 |
| Prev. close | $1.98 | 52-week low | $1.55 |
| Day low | $1.87 | Volume | 245,300 |
| Day high | $2.09 | Avg. volume | 177,293 |
| 50-day MA | $3.20 | Dividend yield | N/A |
| 200-day MA | $10.85 | Market Cap | 72.23M |
Cyteir Therapeutics, Inc. (CYT) Company Bio
Cyteir Therapeutics, Inc. operates as a clinical-stage oncology company that develops novel therapeutics based on the biology of DNA repair for the treatment of cancer and synthetic lethality therapeutics for autoimmune diseases. The company engages in manufacturing therapeutics that provide precision targeting of key DNA repair factors to induce diseased cells to self-destruct by DNA damage overload and uses an integrated drug development platform that modulates the imbalance between DNA damage and repair for the therapeutic effect to deliver a pipeline of small molecule therapeutics with a range of potential disease state applications. It provides CYT-0851, an oral small-molecule inhibitor of RAD51-mediated DNA repair. It focuses on providing treatments for a range of hematological malignancies, solid tumors, and chronic autoimmune disorders. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
Latest CYT News From Around the Web
Below are the latest news stories about Cyteir Therapeutics Inc that investors may wish to consider to help them evaluate CYT as an investment opportunity.
Cyteir Therapeutics Announces the Appointment of Stephen Sands to Board of DirectorsLEXINGTON, Mass., February 24, 2022--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the appointment of Stephen Sands to its Board of Directors, to serve as a Class I director, effective as of February 22, 2022. Mr. Sands was also appointed to serve as a member of the Audit Committee. In connection with Mr. Sands’ appointment, the Board also increased the size of t |
Bargain Shopping? 3 “Strong Buy” Stocks That Are Down Over 50%Who doesn’t like a bargain? In these days, with price inflation hitting hard, we all want to find the best price on every purchase – and that includes our stock purchases. Bargain-conscious investors can still find those fundamentally solid stocks that are trading low; this is the essence of successful stock investing. To make it easy, we’ve done some of the background research. We’ve located three stocks that are down 50% or more, and confirmed that these are Strong Buy stocks, that have gotten plenty of recent approval from the Street’s stock pros. |
Cyteir begins dosing in phase 2 study of CYT-0851 to treat blood cancers, solid tumorsCyteir Therapeutics (NASDAQ:CYT) said the first patient was dosed in a phase 2 expansion cohort of a phase 1/2 trial of CYT-0851 being evaluated for treating hematologic malignancies and solid tumors. "This signal-seeking study in six different cancers will give us the data that may allow us to advance CYT-0851 into a... |
Cyteir Therapeutics Announces First Patient Dosed in Phase 2 with CYT-0851LEXINGTON, Mass., February 08, 2022--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that the first patient has been dosed in a Phase 2 expansion cohort study of CYT-0851 monotherapy that is part of the Phase 1/2 trial. CYT-0851 is being evaluated for the treatment of hematologic malignancies and solid tumors. |
Cyteir Therapeutics Announces the Appointment of John F. Thero to Board of DirectorsLEXINGTON, Mass., February 07, 2022--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the appointment of John F. Thero to its board of directors. Mr. Thero will chair the audit committee. His appointment will increase the number of Cyteir board directors from eight to nine. |
CYT Price Returns
| 1-mo | -36.05% |
| 3-mo | N/A |
| 6-mo | -86.99% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -82.06% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...